Aileron Therapeutics, Inc. (Nasdaq:ALRN)
Health Care/Life Sciences • Biotechnology
CIK 1420565
Company
Aileron Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Waltham, MA.
Address
738 Main Street
No. 398
Waltham, Massachusetts 02451
738 Main Street
No. 398
Waltham, Massachusetts 02451
Employees
6
6
Stock Info
Key Executives
Board Of Directors
|
Chief Executive Officer & Director Manuel C Alves Aivado MD, PhD |
|
Chairman Josef H Von Rickenbach MBA |
|
Lead Independent Director Reinhard J Ambros PhD |
SEC filings
| Date | Form | Event |
|---|---|---|
| 22 Aug, 2024 | 4 | |
| 22 Aug, 2024 | 4 | |
| 22 Aug, 2024 | 4 | |
| 22 Aug, 2024 | 4 | |
| 22 Aug, 2024 | 4 | |
| 21 Aug, 2024 | 8-K | |
| 14 Aug, 2024 | 10-Q | |
| 14 Aug, 2024 | 8-K | |
| 26 Jul, 2024 | 424B5 | |
| 26 Jul, 2024 | 8-K | |
| 26 Jul, 2024 | 424B5 | |
| 9 Jul, 2024 | DEFA14A | |
| 9 Jul, 2024 | ARS | |
| 9 Jul, 2024 | DEF 14A | |
| 17 Jun, 2024 | 4 | |
| 12 Jun, 2024 | 4 | |
| 7 Jun, 2024 | 4 | |
| 5 Jun, 2024 | 8-K | |
| 16 May, 2024 | 3 | |
| 16 May, 2024 | 8-K | |
| 15 May, 2024 | 8-K | |
| 15 May, 2024 | 10-Q | |
| 14 May, 2024 | 4/A | |
| 1 May, 2024 | S-8 | |
| 1 May, 2024 | 8-K | |
| 1 May, 2024 | 4 | |
| 1 May, 2024 | 8-K | |
| 1 May, 2024 | FWP | |
| 1 May, 2024 | 424B5 | |
| 30 Apr, 2024 | 3 | |
| 29 Apr, 2024 | 10-K/A | |
| 29 Apr, 2024 | 144 | |
| 16 Apr, 2024 | SC 13D/A | |
| 15 Apr, 2024 | 8-K | |
| 15 Apr, 2024 | 10-K | |
| 10 Apr, 2024 | 4/A | |
| 10 Apr, 2024 | 4/A | |
| 2 Apr, 2024 | 3 | |
| 1 Apr, 2024 | NT 10-K | |
| 29 Mar, 2024 | 8-K | |
| 15 Mar, 2024 | 8-K | CEO Change |
| 6 Mar, 2024 | 4 | |
| 5 Mar, 2024 | SC 13G | |
| 5 Mar, 2024 | SC 13D/A | |
| 1 Mar, 2024 | 4 | |
| 1 Mar, 2024 | 8-K | |
| 1 Mar, 2024 | 4 | |
| 29 Feb, 2024 | 8-K | |
| 14 Feb, 2024 | SC 13G/A | |
| 13 Feb, 2024 | 8-K | |
| 5 Feb, 2024 | SC 13G/A | |
| 5 Feb, 2024 | EFFECT | |
| 1 Feb, 2024 | CORRESP | |
| 1 Feb, 2024 | UPLOAD | |
| 31 Jan, 2024 | DEFA14A | |
| 29 Jan, 2024 | ARS | |
| 29 Jan, 2024 | DEF 14A | |
| 29 Jan, 2024 | S-3 | |
| 29 Jan, 2024 | S-8 | |
| 29 Jan, 2024 | 8-K | |
| 25 Jan, 2024 | 8-K | |
| 11 Jan, 2024 | 8-K/A | |
| 10 Jan, 2024 | 8-K | |
| 18 Dec, 2023 | 4 | |
| 21 Nov, 2023 | 4 | |
| 16 Nov, 2023 | D | |
| 13 Nov, 2023 | SC 13G | |
| 3 Nov, 2023 | SC 13D/A | |
| 2 Nov, 2023 | 4 | |
| 2 Nov, 2023 | 3 | |
| 2 Nov, 2023 | 3 | |
| 2 Nov, 2023 | 3 | |
| 2 Nov, 2023 | 4 | |
| 31 Oct, 2023 | 8-K | |
| 13 Oct, 2023 | 10-Q | |
| 11 Aug, 2023 | 10-Q | |
| 8 May, 2023 | 10-Q | |
| 28 Apr, 2023 | 10-K/A | |
| 20 Mar, 2023 | 10-K | |
| 23 Feb, 2023 | 8-K | |
| 14 Feb, 2023 | SC 13G/A | |
| 14 Feb, 2023 | SC 13G/A | |
| 10 Nov, 2022 | 8-K | |
| 1 Nov, 2022 | 10-Q | |
| 15 Aug, 2022 | 10-Q | |
| 8 Jul, 2022 | 8-K | |
| 29 Jun, 2022 | 8-K | |
| 21 Jun, 2022 | 424B5 | |
| 17 Jun, 2022 | 4 | |
| 17 Jun, 2022 | 4 | |
| 17 Jun, 2022 | 3 | |
| 17 Jun, 2022 | 4 | |
| 17 Jun, 2022 | 4 | |
| 17 Jun, 2022 | 4 | |
| 17 Jun, 2022 | 4 | |
| 16 Jun, 2022 | 8-K | |
| 16 Jun, 2022 | EFFECT | |
| 14 Jun, 2022 | UPLOAD | |
| 14 Jun, 2022 | CORRESP | |
| 13 Jun, 2022 | DEL AM | |
| 8 Jun, 2022 | 8-K | |
| 8 Jun, 2022 | S-3 | |
| 7 Jun, 2022 | 8-K | CEO Change |
| 5 May, 2022 | 10-Q | |
| 29 Apr, 2022 | DEF 14A | |
| 29 Apr, 2022 | 8-K | |
| 29 Apr, 2022 | DEFA14A | |
| 15 Apr, 2022 | 424B5 | |
| 15 Apr, 2022 | PRE 14A | |
| 30 Mar, 2022 | 4/A | |
| 30 Mar, 2022 | 4/A | |
| 30 Mar, 2022 | 4/A | |
| 30 Mar, 2022 | 4/A | |
| 28 Mar, 2022 | 10-K | |
| 24 Mar, 2022 | 4 | |
| 24 Mar, 2022 | 4 | |
| 24 Mar, 2022 | 4 | |
| 24 Mar, 2022 | 4 | |
| 14 Feb, 2022 | SC 13G/A | |
| 5 Jan, 2022 | 8-K | |
| 7 Dec, 2021 | 8-K | |
| 12 Nov, 2021 | 10-Q | |
| 17 Sep, 2021 | 8-K | |
| 13 Sep, 2021 | 8-K | |
| 11 Aug, 2021 | S-8 | |
| 11 Aug, 2021 | 10-Q | |
| 1 Jul, 2021 | 8-K | |
| 17 Jun, 2021 | 4 | |
| 17 Jun, 2021 | 4 | |
| 17 Jun, 2021 | 8-K | |
| 17 Jun, 2021 | 4 | |
| 17 Jun, 2021 | 4 | |
| 17 Jun, 2021 | 4 | |
| 17 Jun, 2021 | 4 | |
| 17 Jun, 2021 | 4 | |
| 17 Jun, 2021 | 4 | |
| 17 Jun, 2021 | 4 | |
| 17 Jun, 2021 | 4 | |
| 11 May, 2021 | 10-Q | |
| 28 Apr, 2021 | DEFA14A | |
| 28 Apr, 2021 | DEF 14A | |
| 16 Apr, 2021 | PRE 14A | |
| 31 Mar, 2021 | 8-K | |
| 24 Mar, 2021 | 10-K | |
| 24 Mar, 2021 | S-8 | |
| 2 Mar, 2021 | 8-K | |
| 10 Feb, 2021 | SC 13G/A | |
| 9 Feb, 2021 | EFFECT | |
| 9 Feb, 2021 | SC 13G/A | |
| 5 Feb, 2021 | CORRESP | |
| 4 Feb, 2021 | UPLOAD | |
| 29 Jan, 2021 | 8-K | |
| 29 Jan, 2021 | 424B5 | |
| 29 Jan, 2021 | S-3 | |
| 19 Jan, 2021 | SC 13G | |
| 8 Jan, 2021 | SC 13D/A | |
| 8 Jan, 2021 | 4 | |
| 7 Jan, 2021 | 424B5 | |
| 7 Jan, 2021 | 8-K | |
| 6 Jan, 2021 | 8-K |
Last update:2024-03-06 12:54:16.458281
Sign Up to Subscribe
Interested in special situations?
Join Tickerverse
- customize event filters
- create watchlists, bookmarks
- get email notifications for the latest special situations
- browse and analyze public companies, executives and SEC filings
Tickerverse is a great way to find investment opportunities in corporate actions.
By signing up you agree to our Terms of Service and Privacy Policy.